Date: 2012-11-20
Type of information: R&D agreement
Compound:
Company: Shire (UK) Boston Children’s Hospital (USA)
Therapeutic area: Rare diseases
Type agreement: R&D
Action mechanism:
Disease: undisclosed rare pediatric diseases with high unmet medical need
Details: Shire and Boston Children’s Hospital have announced a three-year, broad research collaboration in rare diseases. The goal of the collaboration is to develop novel therapies to treat a number of rare pediatric diseases with high unmet medical need, thereby leveraging Boston Children’s research expertise and Shire’s development and commercialization capabilities.
Last month, Shire has already concluded a long-term, broad based, multi-indication research collaboration in rare diseases with Fondazione Telethon, for research carried out at the Telethon Institute of Genetics and Medicine (TIGEM). This alliance will facilitate research on 13 undisclosed rare disease indications and has the potential to add multiple, novel therapeutic candidates into Shire’s early stage pipeline.
Financial terms: Under the terms of the agreement, Shire will make an initial upfront payment to Boston Children’s and will have the opportunity to fund selected research programs. The emphasis will be on opportunities that have the potential to deliver a development candidate in less than three years from project initiation. Following the completion of these programs, Shire will have an exclusive option to enter into a licensing agreement for each program. Upon entering into any subsequent licensing agreement, Boston Children’s will be eligible to receive certain development and commercial milestone payments, as well as royalties on product sales from Shire. Shire will have the primary responsibility for any further clinical development and commercialization of products arising from the collaboration.
Latest news:
